By admin 
The Centers for Disease Control and Prevention (CDC) has formally published a new charter for its influential vaccine advisory panel, the Advisory Committee on Immunization Practices (ACIP), a move that significantly broadens the required expertise for members and places increased emphasis on vaccine safety. This development, occurring on April 10, 2026, unfolds amidst a dynamic biopharmaceutical landscape, marked by a substantial Series A financing round for RNA therapeutics innovator Vivatides Therapeutics, strategic licensing agreements in targeted protein degradation between Gilead Sciences and Kymera Therapeutics, and Roche and C4 Therapeutics, and a critical U.S. government contract awarded to Shionogi for antibiotic production to combat drug-resistant bacterial threats. These varied events highlight critical shifts in public health policy, burgeoning biotechnological innovation, and national security preparedness in the biopharma sector.
CDC’s ACIP Undergoes Significant Restructuring
The newly enacted charter for ACIP grants Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. expanded authority to reshape the 15-member committee, which plays a pivotal role in establishing vaccine recommendations for the United States. Historically, ACIP has been comprised primarily of experts in infectious diseases, immunology, pediatrics, and public health. The revised guidelines, however, now explicitly mandate that prospective panelists possess knowledge about "recovery from serious vaccine injuries," a qualification that marks a notable departure from previous requirements. This specific emphasis has drawn considerable attention, with a recent report by The New York Times linking the shift to a petition filed by Aaron Siri, a lawyer known for his litigation against vaccine manufacturers and his prior presentations at ACIP meetings where he voiced concerns regarding vaccine safety.
Beyond the expanded expertise requirements for individual members, the new charter also formalizes the inclusion of several vaccine-skeptical organizations, such as the Independent Medical Alliance, as official "liaisons." These liaisons are designated to assist ACIP work groups in their review of scientific data, a role that traditionally involved established medical and public health associations. The implications of this change are substantial, potentially introducing perspectives into the data review process that diverge from mainstream public health consensus.
This restructuring follows a period of significant contention surrounding ACIP. Just last month, a federal judge issued a ruling that effectively paralyzed the panel, stating that many new members previously chosen by Secretary Kennedy "appear distinctly unqualified." This judicial intervention underscored the growing tensions between the current HHS leadership’s approach to vaccine policy and established scientific and medical norms. Critics argue that the introduction of members and liaisons with stated skepticism about established vaccine science could erode public trust in vaccine recommendations, potentially leading to a decline in vaccination rates and an increase in vaccine-preventable diseases. Public health experts have long emphasized that high vaccination coverage is essential for achieving herd immunity, protecting vulnerable populations, and preventing outbreaks of infectious diseases. Any perceived weakening of the scientific rigor or independence of ACIP could have profound consequences for national public health infrastructure and global health security.
The ACIP’s recommendations are not merely advisory; they form the basis for state vaccination mandates, insurance coverage decisions, and clinical practice guidelines across the nation. The panel’s historical integrity has been rooted in its objective, evidence-based assessments, free from political or ideological influence. The recent changes, therefore, prompt a critical examination of the balance between incorporating diverse perspectives and maintaining the scientific credibility essential for public health policymaking. The coming months will likely reveal the practical impact of these charter revisions on ACIP’s function, its recommendations, and ultimately, public health outcomes.
Vivatides Therapeutics Secures $54 Million for Extrahepatic RNA Therapies
In a significant boost for the burgeoning field of RNA therapeutics, Vivatides Therapeutics, a company operating out of Suzhou, China, and Boston, Massachusetts, announced an oversubscribed $54 million Series A financing round. This substantial investment is earmarked to accelerate the development of next-generation RNA drugs with a particular focus on extrahepatic delivery – meaning therapies designed to reach tissues and organs beyond the liver.
RNA-based therapies, including messenger RNA (mRNA) vaccines, antisense oligonucleotides (ASOs), and small interfering RNA (siRNA), have revolutionized medicine in recent years, particularly with the rapid development of COVID-19 mRNA vaccines. However, a persistent challenge in the field has been the effective and safe delivery of these nucleic acid therapies to target cells outside the liver. The liver naturally takes up many intravenously administered drugs, making it an easier target, but limiting the scope of RNA therapeutics for systemic diseases or conditions affecting other vital organs like the heart, lungs, or brain.
Vivatides Therapeutics claims to have developed a "differentiated" method for overcoming this crucial delivery hurdle. Their proprietary platform aims to enable precise targeting of RNA payloads to specific extrahepatic tissues, thereby unlocking a vast array of previously untreatable diseases. The company stated that its approach is applicable to both ASOs and siRNA, two well-established classes of nucleic acid therapies that have shown immense promise in treating genetic disorders and various other conditions. Antisense oligonucleotides work by modulating gene expression at the RNA level, while siRNAs function by "silencing" specific genes, preventing the production of disease-causing proteins.
The Series A round, co-led by prominent venture capital firm Qiming Venture Partners, signifies strong investor confidence in Vivatides’ technology and its potential to expand the therapeutic reach of RNA medicines. The funds will be critical in advancing "multiple" programs into clinical development, a pivotal step in translating promising preclinical research into potential treatments for patients. The global market for RNA therapeutics is projected to grow exponentially, driven by ongoing research, technological advancements in delivery systems, and the expanding pipeline of drug candidates. Companies capable of safely and effectively delivering RNA drugs to a wider range of tissues are poised to capture a significant share of this rapidly evolving market, offering hope for patients with diseases that currently lack effective treatment options. Vivatides’ emergence underscores the ongoing innovation and global competition within the biotech industry to push the boundaries of genetic medicine.
Strategic Moves in Targeted Protein Degradation: Gilead and Roche Make Key Acquisitions
The innovative field of targeted protein degradation (TPD) continues to attract significant investment and strategic partnerships from major pharmaceutical players, as evidenced by two notable deals announced this week. Gilead Sciences and Roche have both made moves to bolster their pipelines with advanced protein-degrading drug candidates, highlighting the growing confidence in this novel therapeutic modality.
On Thursday, Gilead Sciences announced it had exercised its option to license a protein-degrading drug from Kymera Therapeutics. This move grants Gilead full rights to KT-200, a preclinical drug candidate meticulously designed to degrade Cyclin-dependent kinase 2 (CDK2). CDK2 is a well-established driver of tumor growth, particularly in various cancers, making it a highly sought-after target for oncology therapeutics. While traditional approaches have focused on inhibiting CDK2 activity, protein degraders aim to eliminate the protein entirely, potentially offering a more profound and durable therapeutic effect, especially in cases where cancers develop resistance to kinase inhibitors.
Gilead’s option to KT-200 was secured through a comprehensive deal struck with Kymera last June. The exercise of this option comes with a payment of $45 million to Kymera, reflecting the perceived value and potential of KT-200. The TPD landscape is highly competitive, with numerous biotech companies and academic labs exploring various degradation platforms, including PROTACs (proteolysis-targeting chimeras) and molecular glues. The ongoing challenge for these companies is to demonstrate that their degradation approaches offer superior efficacy and safety profiles compared to traditional small-molecule inhibitors or other cancer therapies. Gilead’s commitment to KT-200 signals its strategic intent to diversify its oncology portfolio with cutting-edge modalities.
In parallel, Roche also ventured deeper into targeted protein degradation through a new partnership with C4 Therapeutics, announced on the same day. This collaboration is centered on the exciting frontier of "degrader-antibody conjugates" (DACs). DACs represent a fusion of two powerful therapeutic strategies: the precise targeting capability of antibodies, which can deliver drugs specifically to cancer cells, and the potent protein-degrading mechanism of small molecules. This innovative approach aims to enhance the specificity and therapeutic index of degraders, minimizing off-target effects and maximizing efficacy in tumor cells.
The concept of DACs has been gaining considerable traction in the biopharmaceutical industry, with several companies actively exploring this modality. The Roche-C4 Therapeutics alliance will focus on developing new cancer medicines using this platform. The partners will collaborate on up to two programs, targeting undisclosed oncology targets. Under the terms of the agreement, C4 Therapeutics will be responsible for designing the degrader payloads, leveraging its expertise in TPD chemistry. Roche, in turn, will lead the development of the antibody component and the linking molecule that connects the antibody to the degrader. C4 Therapeutics will receive an upfront payment of $20 million, with the potential to earn over $1 billion in total milestone payments if the programs achieve clinical and commercial success. This substantial financial commitment from Roche underscores the pharmaceutical giant’s belief in the transformative potential of DAC technology to create highly targeted and effective cancer treatments, potentially addressing unmet needs in resistant or difficult-to-treat malignancies.
Shionogi Secures U.S. Government Contract to Combat Drug-Resistant Bacteria
In a crucial development for national health security, the U.S. government on Wednesday awarded Shionogi, a Japanese pharmaceutical company, a significant contract to bolster the production and availability of an antibiotic capable of thwarting drug-resistant bacteria. The deal, facilitated through the Biomedical Advanced Research and Development Authority (BARDA) under Project BioShield, addresses the escalating global threat of antimicrobial resistance (AMR).
Under the terms of the contract, Shionogi will undertake several key initiatives to enhance the U.S.’s preparedness against bacterial biothreats and drug-resistant infections. Firstly, the company will establish a dedicated U.S. manufacturing site for its advanced antibiotic, Fetroja (cefiderocol). This domestic production capability is vital for ensuring a secure and reliable supply chain, reducing reliance on foreign manufacturing, and enhancing national readiness in the event of a public health crisis or biodefense scenario.
Secondly, the contract mandates that Shionogi advance Fetroja for the treatment of infections caused by certain "high priority biothreat pathogens." These pathogens often include bacteria that could be intentionally released as biological weapons or naturally occurring highly virulent strains with significant pandemic potential, such as those responsible for anthrax, plague, or tularemia. Fetroja, a siderophore cephalosporin, is designed to overcome multiple resistance mechanisms employed by Gram-negative bacteria, including carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa, which are among the most challenging to treat. By specifically targeting these resilient bacteria, Fetroja can provide a critical therapeutic option in scenarios where conventional antibiotics are ineffective.
Finally, Shionogi will seek Food and Drug Administration (FDA) clearance for the use of Fetroja in pediatric populations. The development of antibiotics specifically formulated and approved for children is often a neglected area, yet it is critically important. Children are particularly vulnerable to serious infections, and having appropriate treatment options is essential for their care and for preventing the spread of resistance.
Shionogi will initially receive $119 million as part of this agreement, with the potential for the total value of the contract to reach up to $482 million. This substantial investment from the U.S. government underscores the urgency and severity of the AMR crisis. The CDC estimates that more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, resulting in over 35,000 deaths. Beyond the human toll, AMR also imposes a significant economic burden on healthcare systems. BARDA, a component of the HHS Office of the Assistant Secretary for Preparedness and Response, plays a crucial role in developing and procuring medical countermeasures to protect the nation from chemical, biological, radiological, and nuclear threats, as well as emerging infectious diseases. This contract for Fetroja represents a proactive step in strengthening the U.S. medical countermeasure infrastructure and ensuring that frontline healthcare providers have access to effective tools in the ongoing battle against drug-resistant superbugs.